Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026)

Sol-Gel Technologies (SLGL) reported Total Non-Current Liabilities of $831000.0 for Q1 2026, down 64.15% year-over-year from $2.3 million in Q1 2025, and down 11.12% quarter-over-quarter from $935000.0 in Q4 2025.

Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has 11 years of Total Non-Current Liabilities data on file, last reported at $831000.0 in Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $831000.0, down 64.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $831000.0 (down 64.15% YoY), and the FY2025 annual result was $935000.0, down 45.35% from the prior year.
  • Total Non-Current Liabilities eased to $831000.0 in Q1 2026 per SLGL's latest filing, from $935000.0 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $2.5 million in Q2 2025 and troughed at $831000.0 in Q1 2026.
  • A 5-year average of $1.7 million and a median of $1.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities jumped 95.3% in 2023, then tumbled 64.15% in 2026.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.1 million in 2022, then jumped by 95.3% to $2.1 million in 2023, then dropped by 19.33% to $1.7 million in 2024, then sank by 45.35% to $935000.0 in 2025, then decreased by 11.12% to $831000.0 in 2026.
  • Business Quant data shows SLGL's Total Non-Current Liabilities at $831000.0 in Q1 2026, $935000.0 in Q4 2025, and $2.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Sol-Gel Technologies 207.80 Mn 197.67 Mn - 831,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 831,000.00
Dec 31, 2025 935,000.00
Sep 30, 2025 2.42 Mn
Jun 30, 2025 2.47 Mn
Mar 31, 2025 2.32 Mn
Dec 31, 2024 1.71 Mn
Sep 30, 2024 1.74 Mn
Jun 30, 2024 1.90 Mn
Mar 31, 2024 2.04 Mn
Dec 31, 2023 2.12 Mn
Sep 30, 2023 2.23 Mn
Jun 30, 2023 1.14 Mn
Mar 31, 2023 1.06 Mn
Dec 31, 2022 1.09 Mn
Sep 30, 2022 1.22 Mn
Jun 30, 2022 1.41 Mn
Mar 31, 2022 1.72 Mn
Dec 31, 2021 1.90 Mn
Sep 30, 2021 1.86 Mn
Jun 30, 2021 2.00 Mn